<DOC>
	<DOCNO>NCT00103779</DOCNO>
	<brief_summary>This open-label , multi-dose , Phase I , dose escalation study define safety profile preliminary anti-tumor activity SGN-40 patient refractory recurrent non-Hodgkin B-cell lymphoma .</brief_summary>
	<brief_title>A Safety Study SGN-40 Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>A minimum 3 patient enter dose-level cohort 5 week . A dose-escalation schema employ cohort . The initial dose start 1 mg/kg Day 1 4 follow 2mg/kg Day 8 . Dose escalation occur week 3-5 maximum weekly dose 8 mg/kg . Patients meet criterion least partial response eligible additional 4 weekly dos high dose tolerate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Patients must histological diagnosis B cell nonHodgkin 's lymphoma , include diffuse large Bcell , mantle cell , follicular , small lymphocytic , marginal zone lymphoma World Health Organization criterion . Patients must archive paraffin fresh tumor specimen available immunohistologic evaluation CD40 , CD20 , &amp; CD79a . Patients must relapse lymphoma must fail frontline chemotherapy . Patients receive autologous stem cell transplant must refuse ineligible . Patients must complete radiotherapy , chemotherapy , and/or treatment investigational anticancer agent 4 week prior registration . Patients must complete monoclonal antibody treatment , include rituximab , 6 month prior registration . Patients must complete autologous bone marrow transplant 4 month prior registration . Patient must least one site measurable disease define unidimensional lesion ≥ 2 cm conventional CT scan . Patients must ECOG performance status ≤ 2 life expectancy &gt; 3 month . Patients must follow required baseline laboratory data : Platelet count ≥ 75,000/mm3 , Hemoglobin ≥ 9.0 g/dL , Absolute neutrophil count ≥ 1,250/mm3 , ALT/AST ≤ 2.5 time ULN , Total bilirubin ≤ 1.5 time ULN , Creatinine &lt; 1.5 mg/dL , Females childbearing potential must negative serum βhCG pregnancy test result within 3 day prior first dose SGN40 must agree use effective contraceptive method course study 6 month follow last dose study drug . If deep venous thrombosis vascular even require medical surgical intervention past year , patient must either stable dose anticoagulant therapy least 3 week complete anticoagulant therapy least 3 month prior registration radiographic confirmation thrombosis resolve . Patients must least 18 year age . Patients must available periodic blood sampling , studyrelated assessment management toxicity treat institution . Patients history clinical evidence leptomeningeal central nervous system ( CNS ) lymphoma . Patients document history within 6 month registration cerebral vascular event , myocardial infarction , deep venous thrombosis vascular event require medical surgical intervention . Patients must complete anticoagulant therapy least 3 month prior registration . Prophylactic anticoagulant therapy indwell catheter acceptable . Patients receive allogeneic stem cell transplant . Patients major surgery within 4 week prior registration . Patients know hypersensitivity recombinant proteins excipient contain drug formulation . Patients history another primary malignancy remission least 5 year ( nonmelanoma skin cancer cervical carcinoma situ biopsy squamous intraepithelial lesion PAP smear exempt five year limit ) . Patients active systemic viral , bacterial , fungal infection within four week prior registration . Patients know positivity HIV , hepatitis B hepatitis C infection . Patients history significant chronic recurrent infection require treatment . Patients history migraine severe headache require medical therapy within 12 month enrollment . Patients systemic steroid stable daily dose ( exceed 10 mg prednisone equivalent ) 4 week prior first dose SGN 40 . Patients pregnant breastfeeding . Patients serious underlying medical condition would impair ability receive tolerate plan treatment . Patients dementia alter mental status would preclude understanding and/or rendering inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibody , Monoclonal</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphoma</keyword>
</DOC>